VANCOUVER, Sept. 10, 2019 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN; FWB:1UB; OTCQB: CGNSF) today announced that its technology was featured in Digital Health, a leading source of industry healthcare technology news, published on 9thSeptember 2019.
The article features an in-depth discussion on Cognetivity’s proprietary technology, which can have a significant impact on healthcare providers’ ability to diagnose dementia at an earlier stage than is currently practical using conventional approaches. In the article the company’s CEO, Dr. Sina Habibi discusses the underlying scientific approach, utilizing leading-edge neuroscientific research, that is involved in the design of the company’s Integrated Cognitive Assessment platform. The article also highlights the ongoing multi-center clinical study in the NHS in the UK and the platform’s potential to significantly improve the early detection rates of dementia sufferers, and thus improve patient outcomes in this huge global healthcare challenge.
Cognetivity is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA) for use in medical, commercial and consumer environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity aims to develop the ICA through ongoing clinical studies to the market in North America, Europe and elsewhere in the world.
The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.
The Exchange does not accept responsibility for the adequacy or accuracy of this release
SOURCE Cognetivity Neurosciences Ltd
For further information: Email: firstname.lastname@example.org; For media enquiries contact: Josh Stanbury, Email: email@example.com